Thursday, January 15, 2009

Advaxis beats Anza at EPC

NJBiz reports: Biotechnology firm Advaxis Inc. of North Brunswick, New Jersey announced on Jan. 14 victory in a patent challenge in the European Patent Court in Munich, Germany, over its antigen, called Lovaxin C. In what it claimed is a final ruling that cannot be reversed in the European Union, the court reversed a patent challenge from Anza Therapeutics Inc., a biotechnology firm in Concord, Calif.


Post a Comment

<< Home